People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tectonic Therapeutic, Inc. | — | Biotechnology | Series D+ | $333.1M | $1.7B | 2016 |
| Talaris Therapeutics, Inc. | — | Biotechnology | Series D+ | $115.0M | $4.4B | 2020 |
| ESSA Pharma Inc. | — | Pharmaceuticals | Series B | $56.0M | $1.2B | 2016 |
| VBI Vaccines Inc/BC | — | Pharmaceuticals | Series A | $41.6M | $145.6M | 2016 |
| TYRX, Inc. | — | Other | Series B | $40.7M | $33.2M | 2009 |
Scott Requadt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Scott Requadt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| David Anderson | 1 | 21 |
| Steve Gillis | 1 | 13 |
| Bruce Booth | 1 | 12 |
| Joshua Resnick | 1 | 12 |
| James Martin | 1 | 9 |
| Terry McGuire | 1 | 8 |
| David Wood | 1 | 8 |
| Franklin Berger | 1 | 7 |
| Steven Rubin | 1 | 7 |
| Geoff MacKay | 1 | 5 |
| Ian Clark | 1 | 5 |
| Mark McDade | 1 | 5 |
| PHILLIP B. DONENBERG | 1 | 4 |
| Jeff Baxter | 1 | 4 |
| Timothy A. Springer | 1 | 4 |
| David E. Anderson | 1 | 3 |
| FRANCISCO DIAZ-MITOMA | 1 | 3 |
| Arthur Pappas | 1 | 3 |
| Egidio Nascimento | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.